Guardant Health Inc (GH) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Guardant Health Inc stock (GH) is currently trading at $86.58. Guardant Health Inc PS ratio (Price-to-Sales) is 11.17. Analyst consensus price target for GH is $132.57. WallStSmart rates GH as Sell.
- GH PE ratio analysis and historical PE chart
- GH PS ratio (Price-to-Sales) history and trend
- GH intrinsic value — DCF, Graham Number, EPV models
- GH stock price prediction 2025 2026 2027 2028 2029 2030
- GH fair value vs current price
- GH insider transactions and insider buying
- Is GH undervalued or overvalued?
- Guardant Health Inc financial analysis — revenue, earnings, cash flow
- GH Piotroski F-Score and Altman Z-Score
- GH analyst price target and Smart Rating
Guardant Health Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Guardant Health Inc (GH) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in market cap, revenue growth, institutional own.. Concerns around return on equity and operating margin. Significant fundamental concerns warrant caution or avoidance.
Guardant Health Inc (GH) Key Strengths (3)
Revenue surging 39.40% year-over-year
101.29% of shares held by major funds and institutions
Large-cap company with substantial market presence
Supporting Valuation Data
Guardant Health Inc (GH) Areas to Watch (5)
Company is destroying shareholder value
Losing money on operations
Company is losing money with a negative profit margin
Very expensive at 11.2x annual revenue
Very expensive at 55.7x book value
Supporting Valuation Data
Guardant Health Inc (GH) Detailed Analysis Report
Overall Assessment
This company scores 29/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 3 register as strengths (avg 9.7/10) while 5 fall into concern territory (avg 0.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Revenue Growth, Institutional Own., Market Cap. Growth metrics are encouraging with Revenue Growth at 39.40%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Profit Margin. Some valuation metrics including Price/Sales (11.17), Price/Book (55.67) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -4584.00%, Operating Margin at -42.90%, Profit Margin at -42.40%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -4584.00% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 39.40% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
GH Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
GH's Price-to-Sales ratio of 11.17x sits near its historical average of 11.81x (0th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 11% below its historical high of 12.54x set in Mar 2026, and 0% above its historical low of 11.17x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~12.5x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Guardant Health Inc (GH) · HEALTHCARE › DIAGNOSTICS & RESEARCH
The Big Picture
Guardant Health Inc is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 982M with 39% growth year-over-year. The company is currently unprofitable, posting a -42.4% profit margin.
Key Findings
Revenue growing at 39% YoY, reaching 982M. This pace significantly outperforms most DIAGNOSTICS & RESEARCH peers.
Debt-to-equity ratio of -3.74 indicates a conservative balance sheet with 580M in cash.
The company is unprofitable with a -42.4% profit margin. The path to breakeven will be the key catalyst.
Free cash flow is -42M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Guardant Health Inc maintain 39%+ revenue growth, or will competition slow it down?
Volatility is elevated with a beta of 1.69, so expect amplified moves relative to the broader market.
Sector dynamics: monitor DIAGNOSTICS & RESEARCH industry trends, competitive moves, and regulatory changes that could impact Guardant Health Inc.
Bottom Line
Guardant Health Inc is a high-conviction growth story with revenue accelerating at 39% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin -42.4% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Guardant Health Inc(GH)
NASDAQ
HEALTHCARE
DIAGNOSTICS & RESEARCH
USA
Guardant Health, Inc., a precision oncology company, offers blood testing, data sets, and testing in the United States and internationally. The company is headquartered in Redwood City, California.